[Shuanglu Pharmaceutical: gemcitabine Hydrochloride for injection obtains Drug Registration Certificate] June 19, Shuanglu Pharmaceutical announced that the company recently received the Drug Registration Certificate of gemcitabine Hydrochloride for injection (0.2g Gemcitabine 1g) approved and issued by the State Drug Administration. The drug is mainly used in the treatment of locally advanced or metastatic non-small cell lung cancer, locally advanced or metastatic pancreatic cancer. Gemcitabine combined with paclitaxel can be used to treat relapse after adjuvant / neoadjuvant chemotherapy. Unresectable, locally recurrent or metastatic breast cancer.